23andMe Investor Presentation Deck

23ME'610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy >>> CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway CD200 is highly expressed in a subset of human cancers and its binding to CD200R1 decreases the ability of T cells to recognize and kill cancer cells 23ME'610 is a potent, effectorless, monoclonal antibody against CD200R1 that has the potential to restore T-cell killing of cancer cells >>> The Phase 1 dose escalation study of 23ME'610 in patients with advanced solid malignancies was initiated in January 2022 Further evaluation of 23ME'610 will occur in expansion cohorts for adolescents and for specific disease areas

View entire presentation